Effect of Duration and Amplitude of Direct Current When Lidocaine is Delivered by Iontophoresis by Saliba, Susan A. et al.
University of Kentucky
UKnowledge
Rehabilitation Sciences Faculty Publications Rehabilitation Sciences
12-6-2011
Effect of Duration and Amplitude of Direct
Current When Lidocaine is Delivered by
Iontophoresis
Susan A. Saliba
University of Virginia
Courtney L. Teeter-Heyl
Ortho Rehab & Specialty Centers
Patrick O. McKeon
University of Kentucky, patrick.mckeon@uky.edu
Christopher D. Ingeroll
Central Michigan University
Ethan N. Saliba
University of Virginia
Right click to open a feedback form in a new tab to let us know how this document benefits you.
Follow this and additional works at: https://uknowledge.uky.edu/rehabsci_facpub
Part of the Pharmacy and Pharmaceutical Sciences Commons, and the Rehabilitation and
Therapy Commons
This Article is brought to you for free and open access by the Rehabilitation Sciences at UKnowledge. It has been accepted for inclusion in
Rehabilitation Sciences Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact
UKnowledge@lsv.uky.edu.
Repository Citation
Saliba, Susan A.; Teeter-Heyl, Courtney L.; McKeon, Patrick O.; Ingeroll, Christopher D.; and Saliba, Ethan N., "Effect of Duration
and Amplitude of Direct Current When Lidocaine is Delivered by Iontophoresis" (2011). Rehabilitation Sciences Faculty Publications.
77.
https://uknowledge.uky.edu/rehabsci_facpub/77
Effect of Duration and Amplitude of Direct Current When Lidocaine is Delivered by Iontophoresis
Notes/Citation Information
Published in Pharmaceutics, v. 3, issue 4, p. 923-931.
© 2011 by the authors; licensee MDPI, Basel, Switzerland.
This article is an open access article distributed under the terms and conditions of the Creative Commons
Attribution license (http://creativecommons.org/licenses/by/3.0/).
Digital Object Identifier (DOI)
https://doi.org/10.3390/pharmaceutics3040923
This article is available at UKnowledge: https://uknowledge.uky.edu/rehabsci_facpub/77
Pharmaceutics 2011, 3, 923-931; doi:10.3390/pharmaceutics3040923 
 
pharmaceutics
ISSN 1999-4923 
www.mdpi.com/journal/pharmaceutics 
Article 
Effect of Duration and Amplitude of Direct Current when 
Lidocaine Is Delivered by Iontophoresis 
Susan A. Saliba 1,*, Courtney L. Teeter-Heyl 2, Patrick McKeon 3, Christopher D. Ingeroll 4 and 
Ethan N. Saliba 5 
1 University of Virginia, PO Box 400407, Charlottesville, VA 22904, USA 
2 Ortho Rehab & Specialty Centers, 3808 Rose Point Cove, PO Box 241574, Little Rock, AR 72223, 
USA; E-Mail: clt9b@yahoo.com 
3 University of Kentucky, 900 South Limestone Street, Lexington, KY 40536, USA;  
E-Mail: McKeon@uky.edu 
4 Central Michigan University, 2217 Health Professions Building, Mt. Pleasant, MI 48859, USA;  
E-Mail: inger1c@cmich.edu 
5 University of Virginia, PO Box 400834, Charlottesville, VA 22904, USA; E-Mail: ens@virginia.edu 
* Author to whom correspondence should be addressed; E-Mail: saf8u@virginia.edu;  
Tel.: +1-243-4033; Fax: +1-434-924-1389. 
Received: 8 October 2011; in revised form: 25 November 2011 / Accepted: 5 December 2011 /  
Published: 6 December 2011 
 
Abstract: Dosage for the galvanic stimulation for iontophoresis varies. Clinicians 
manipulate the duration or the amplitude of the current, but it is not known which is more 
effective. We compared the anesthetic effect of lidocaine HCL (2%) by manipulating the 
current parameters on 21 healthy volunteers (age: 21.2 ± 4.2, height 170.7 ± 10.2 cm, mass 
82.1 ± 19.2 kg). Three conditions were administered in a random order using a Phoresor 
II® with 2 mL, 2% lidocaine HCL in an iontophoresis electrode. (1) HASD (40 mA*min): 
High amplitude (4 mA), short duration (10 min); (2) LALD (40 mA.min): Low amplitude 
(2 mA), long duration (20 min); (3) Sham condition (0 mA, 20 min). Semmes-Weinstein 
monofilament (SWM) scores were taken pre and post intervention to measure sensation 
changes. Two-way ANOVA with repeated measures was used to compare sensation. Both 
iontophoresis treatments: LALD (4.2 ± 0.32 mm) and HASD (4.2 ± 0.52 mm) significantly 
increased SWM scores, indicating an increase in anesthesia, compared to the sham 
condition (3.6 ± 0.06 mm) p < 0.05. Neither LALD nor HASD was more effective and 
there was no difference in anesthesia with the sham. Lidocaine delivered via iontophoresis 
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reduces cutaneous sensation. However, there was no benefit in either a HASD or LALD 
treatment. 
Keywords: percutaneous drug delivery; physical therapy; transdermal; electrical 
stimulation; electroporation 
 
1. Introduction  
Iontophoresis is a noninvasive method of electrically administering medications in their ionic  
form into the body through the use of a direct current [1,2]. Iontophoresis is sterile, noninvasive, is less 
painful than a local injection and avoids the first pass through the hepatic system. Furthermore, 
iontophoresis can be applied directly to an injured or painful site, resulting in a local effect of the 
treatment [3]. The evidence to support the use of iontophoresis to treat pain and inflammation associated 
with musculoskeletal injuries remains limited [4–8]. However, most research that investigates the 
efficacy of iontophoresis focuses on the parameters of drug delivery rather than examining the current 
parameters to optimize treatment. Factors such as skin permeability and passive diffusion based on the 
concentration of the medication should be considered as well as the electro-repulsive components to 
determine the best method of clinical application of iontophoresis [1,9]. Although in vitro studies are 
effective in determining the ability of electrical current to enhance the diffusion across synthetic 
membranes [10], they do not consider the time that the medication is in contact with the skin that may 
affect the overall treatment outcome. 
Using Coulomb’s Law, the dosage for the electrical component of iontophoresis is described in 
milliamp minutes (mA*min) or the amplitude of the galvanic current (milliamps or mA) multiplied by 
amount of time delivered (minutes). Treatment guidelines suggested by manufacturers imply that both 
factors of the dosage (amplitude and time) will result in similar affects on drug delivery, although this 
hypothesis has not been tested clinically. Most commercial units electronically adjust the treatment 
time after the clinician adjusts the current amplitude based on the perceived comfort by the patient.  
The amplitudes available in these devices are generally well tolerated so patients often request a shorter 
treatment time with higher amplitude current to minimize the time needed in the clinic. The 
iontophoresis parameters vary widely in clinical trials, ultimately affecting the ability to standardize 
clinical treatments to comprehensively evaluate the effectiveness of this modality. Therefore, it is 
important to mechanistically determine which component of the dosage, either time or current amplitude, 
has a greater affect on drug absorption. 
The purpose of this study was to compare the reduction in cutaneous sensation following two 
iontophoresis protocols with the same 40 mA*min dosage to a sham treatment. Both iontophoresis 
treatments used 2% lidocaine HCL and were delivered with a high amplitude/short duration (HASD) 
or a low amplitude/long duration (LALD) method. The amount of skin anesthesia following each 
treatment was measured using Semmes-Weinstein monofilaments (SWM).  
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2. Experimental Section  
A double-blind crossover design was used for this study. Twenty-one healthy subjects (13 male,  
8 female); (age 21.2 ± 4.3 years; height 170.7 ± 10.3 cm, mass 82.1 ± 19.2 kg) volunteered for this study. 
Subjects had no known allergies to lidocaine or adhesives, there were no neurological pathology of the 
upper body and participants were free from skin abnormalities in the area of electrode placement. The 
Institutional Review Board for Health Sciences Research approved the study and all subjects signed 
informed consent forms prior to enrollment. 
The independent variables were the treatment condition: (1) HASD: 40 mA*min with 2% lidocaine 
HCL applied at an amplitude of 4 mA for 10 min; (2) LALD: 40 mA*min with 2% lidocaine HCL at 
an amplitude of 2 mA for 20 min; (3) Sham: zero amplitude for 20 min using 2% lidocaine HCL. All 
conditions utilized standard commercial iontophoresis electrodes with 2 mL of 2% lidocaine HCL 
injected into the bladder of the active, positive electrode. The HASD treatment was delayed for 10 min 
prior to application to make the testing time consistent among groups. Before each condition and 
within 5 min following each condition, SWM were used to quantify cutaneous sensation by an 
investigator who was blinded to the treatment condition. Each treatment was separated by 48 hours and 
we alternated the application to the right and left forearm at each condition to prevent a cumulative 
effect between treatments.  
The order of treatments was randomly assigned and the order was counterbalanced. The dependent 
variable was score on the SWM test (Smith and Nephew, Inc., Germantown, WI), which has been 
validated for use in sensory research [11,12]. The monofilaments were applied to the skin with enough 
force to cause each filament to buckle into the shape of a crescent moon. SWM exam started with  
the smallest diameter monofilament, testing every other diameter monofilament until the monofilament 
was perceived. When a “yes” response was achieved, the next smallest monofilament was tested. If  
that monofilament received a “yes” response then that diameter was recorded. If the next smallest 
monofilament received a “no” response then the monofilament that received a “yes” response was 
recorded. A no-touch condition during testing was randomly incorporated. This procedure has a reported 
intertester and intratester reliability of 92% [13] and 89% [14] respectively with a sensitivity of 70% and 
specificity of 90% [15]. There are no units for the SWM since the value is associated with the 
logarithm of the force produced, expressed in tenths of a milligram [16]. Neither the subject nor the 
clinician administering the test was aware of the condition assigned, and the participant was draped 
during the sensory exam so that he or she could not see the test being performed. 
The Phoresor II Auto Model PM850 (IOMED, Salt Lake City, UT) was used to deliver the direct 
current using medium-size TransQE electrodes (IOMED, Salt Lake City, UT). The areas of electrode 
placement were cleaned with an alcohol pad and dried. The active electrode with the medication applied 
was placed on the volar aspect of the anterior forearm, 4 inches distal to the anti-cubital crease. The 
dispersive, negative electrode was placed on the same arm, 4 inches proximal to the anti-cubital crease. 
A mark was made to indicate the bladder portion of the active electrode. All monofilament testing was 
done within that demarcation to provide consistency. 
A two-way ANOVA with repeated measures was used to examine the effects of amplitude and 
duration on the SWM score. The independent variables were the condition (HASD, LALD, and sham) 
and test (pre and post). The dependent variable was smallest monofilament diameter perceived in the 
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treatment area. The a priori alpha level was set at P < 0.05. Post Hoc pairwise comparisons were 
performed to explain significant interactions.  
3. Results and Discussion 
Data are presented in Table 1. There was a significant test by condition interaction (F2,40 = 6.950,  
P = 0.003). Pairwise comparisons revealed that there were no significant differences among any of the 
pretest measures, nor was there a difference in the pre and posttest scores in the sham condition. There 
was a significant difference between the post-test sensation measures for the LALD compared to  
the control condition (P = 0.001), as well as a significant difference between the HASD and control 
condition (P = 0.001), graphically represented in Figure 1. Both the HASD and the LALD conditions had 
strong effect sizes. However there was no significant difference between LALD and HASD post-test 
scores. Confidence intervals are reported in Figure 2. 
Table 1. Means and standard deviations by condition. 
Condition Test SWM Mean ± SD 
Effect Size 
(Cohen’s d) 
Sham Pre 3.63 ± 0.39 0.20 
 Post 3.70 ± 0.29  
HASD Pre 3.71 ± 0.28 1.52 
 Post 4.17 ± 0.32*  
LALD Pre 3.65 ± 0.37 1.24 
 Post 4.21 ± 0.52*  
Figure 1. Means of Semmes Weinstein monofilament scores by condition and time. 
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Figure 2. Confidence Intervals of each condition, indicating strong effects of both the high 
amplitude/short duration (HASD) and low amplitude/long duration (LALD) conditions. 
 
Although many pharmaceutical agents can be used with iontophoresis, we chose to use lidocaine so 
that the effects of manipulating the electrical current parameters could be examined in a non-invasive 
manner. Lidocaine or other anesthetics have been used in this fashion to examine the effects of either 
phonophoresis [17] or iontophoresis [18–20] mechanistically. Since the dosage or concentration of the 
drug, the site of application, and the total amount of charge applied for each condition remained 
constant, we were able to determine the effects of manipulating the current parameters on the overall 
iontophoretic effect. Similar to previous investigations, we estimated the drug absorption to be 
associated with the degree of cutaneous anesthesia in this model [18]. Our results showed that both the 
HASD and the LALD conditions resulted in significantly greater anesthesia than both pre-tests and the 
sham condition, but there was no superiority of either method. Thus, as hypothesized based on 
Coulomb’s Law, the total charge applied affected the results, rather than the manipulation of the either 
the magnitude of the current or the duration of the stimulation.  
The rate-limiting factor for any transdermal drug delivery system is the stratum corneum of the 
skin. This outermost layer is comprised of keratinized cells and has both lipophilic and hydrophilic 
properties to reduce fluid loss and prevent the absorption of most topical agents [21]. Several strategies 
have been developed to improve transdermal drug delivery and include methods to change the barrier 
properties of the stratum corneum [1], to improve the hydration of the skin [22], or to provide a phyical 
enhancement techniques such as employed by iontophoresis, phonophoresis or electroporation [23]. 
Iontophoresis requires the pharmaceutical agent to be in an ionic form and utilizes an electrorepulsion 
mechanism of low amplitude galvanic current to drive the desired medication through the skin.  
The medication in its ionic form must be the same polarity as the active electrode. The primary 
mechanisms of enhanced transport is through existing pathways such as the hair follicles and sweat 
glands [24] and is often dependent on the amount or concentration of the drug in its ionic form [25]. 
Phonophoresis uses ultrasound energy to enhance the transport of whole molecules through the  
skin [22,26] while electroporation uses a high voltage current of short duration to allow enhanced 
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diffusion of topical agents [27]. Both phonophoresis and electroporation are hypothesized to 
temporarily change the structure of the stratum corneum to enhance the penetration of the drug. 
Factors that are proposed to affect iontophoresis include the physiochemical properties of the 
pharmacological agent such as the concentration, molecular charge and the molecular size.[28] Other 
factors, such as characteristics of the skin should also be considered, particularly if there is a potential 
osmotic effect, similar to electroporation following the application of current. For example, in 
electroporation, there are changes noted in the structure of the stratum corneum [23] and these changes 
have been observed in conjunction with increased permeability of the skin with various current 
waveforms, including biphasic [10,29,30]. From a clinical perspective, it would stand to reason that if 
the electrical current acts on the skin, and the longer the medication is in contact with the skin, the 
greater the chance of transport through the skin using a combination of the mechanisms presented with 
iontophoresis and electroporation [27,31,32].  
This mechanism is being addressed by new commercially produced clinical units, although there is 
little data in the literature to determine their best use for musculoskeletal pathologies. With this 
treatment, current is applied via a “patch” electrode containing the pharmaceutical agent, and the 
medication remains in place for several hours after the treatment, exploiting the passive absorption 
potential. This application would more closely mimic the LALD condition, and has been shown to be a 
factor for continued absorption of lidocaine after the current had ceased [33]. Conversely, the HASD 
condition might permit a greater absorption of the drug as a result of a greater electrorepulsion factor 
of the higher electrical stimulation apmplitude [1]. We did not see a difference in the amount of drug 
absorption when the medication remained in contact with the skin for a longer time. Thus, using this 
model, the electroporetic effect on the skin was likely to minimal, and we observed an iontophoretic 
effect based on the total charge.  
The dosages that we chose to investigate were similar to clinical applications in the treatment of 
musculoskeletal pathologies. The variation in the length of time between the doses was 10 min. Although 
increased passive transport may have occurred within this timeframe, it may have been too short of a 
difference between the two conditions to be able to assess a measureable difference. Likewise, we did 
not investigate the duration of the anesthesia that may further indicate passive diffusion into the dermis. 
Future studies should broaden the variation in the application time or test the difference between a 
standard iontophoresis treatment and an electrophoretic treatment. The electrophoretic treatment would 
incorporate a short electrical stimulation time and much longer topical drug appliation (for hours). 
Lidocaine would be an unlikely surrogate to represent drug absorption in that type of study since the 
half-life of lidocaine is approximately 90 min [34]. Furthermore, lidocaine with epinepherine should be 
explored since the epinepherine would prevent pooling of the drug in the capillaries. 
Iontophoresis has been shown to be an effective method of lidocaine delivery for decreasing 
cutaneous sensation [18,35,36]. Lidocaine blocks the fast-gated sodium channels to inhibit presynaptic 
neurons from depolarizing [34]. Thus, there is an elimination of all sensory information, including pain 
when the drug is absorbed into the dermis. The solution of lidocaine HCL was not designed for topical 
administration, which would likely require some agent such as a chemical enhancer to improve the 
transport through the stratum corneum. The diminished cutaneous response, as measured by the SWM 
indicated increased absorption when the iontophoresis conditions were used, compared to the sham, 
which had no change in anesthesia. Since the sensory effects were diminished, rather than eliminated, 
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we anticipated that we would be able to evaluate a difference in the two treatment conditions using the 
SWM scores. In other words, we did not achieve a ceiling effect with the measurement tool. 
There is generally no consensus in the literature on the manipulation of the amplitude of the current 
or the duration of the treatment [37]. The clinician determines the overall dosage, typically  
40 mA*min, and the current amplitude is adjusted to the patient’s comfort level. There is a maximum 
amplitude on commercial devices to reduce the risk of adverse effects. Often, patients choose a shorter 
iontophoresis treatment (with a higher amplitude) to reduce the overall time required. Chemical burns 
and heat burns have been reported using clinical parameters of iontophoresis [38], however, we did not 
observe any cutaneous changes such as redness at the electrode sites in either condition. Since there 
was no difference in the overall treatment effect, clinicians should continue to use patient feedback, 
particularly for those with sensitive skin to determine their current amplitude. None of our participants 
reported any discomfort from the HASD treatment.  
4. Conclusions  
Using this model of HASD and LALD, there does not appear to be an effect of manipulating the 
individual components of the iontophoresis parameters when the same dosage is applied. However, we 
did not examine the length of time that anesthesia would last. Our results imply that the clinician can 
increase the amplitude of stimulation within patient tolerance to minimize the treatment time, or 
choose a more comfortable, longer duration to elicit an effective iontophoresis application. 
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